Home / Stocks / Fredun Pharmaceuticals L
FREDUN

Fredun Pharmaceuticals L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,708.0

Change

+71.6 (4.38%)

Open

₹1,654.9

Prev. Close

₹1,636.4

Day High

₹1,712.9

Day Low

₹1,624.0

Volume Analysis

Traded

160,966

Delivered

68,392

Delivery %

42.49%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Trading within 3% of its 52-week high (₹1666.0)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (3)

  • •Strong 3-year EPS growth (35.8%)
  • •Strong 3-year revenue growth (32.2%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,828.16 ₹1,770.53 ₹1,739.26 ₹1,681.63 ₹1,650.36 ₹1,592.73 ₹1,561.46
Fibonacci ₹1,770.53 ₹1,736.57 ₹1,715.59 ₹1,681.63 ₹1,647.67 ₹1,626.69 ₹1,592.73
Camarilla ₹1,732.45 ₹1,724.3 ₹1,716.15 ₹1,681.63 ₹1,699.85 ₹1,691.7 ₹1,683.55

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

+11.83%

1 Month

+25.05%

3 Months

+19.06%

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹221.05

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

17.34%

Net margin 6.09% × asset turnover 1.13x × equity multiplier 2.52x

Company Overview

Sector

Healthcare

Market Cap

₹2,548 Cr

P/E (TTM)

48.1

ROE

15.6%

Book Value

₹196.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Fredun Pharmaceuticals L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 58/100. The strongest factor is Growth (100/100), while Cash Flow (1/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹1666.0); promoter holding is falling. Strong 3-year EPS growth (35.8%).

TopFund Score — Fundamentals Quality

58/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

73

Growth

100

Valuation

2

Cash Flow

1

Corporate Governance

45

Momentum

85

Institutional Ownership

53

Business Quality

64

Risk & Volatility

69

Liquidity

72

From Screener.in

  • +Debtor days have improved from 97.8 to 53.2 days.
  • −Stock is trading at 7.61 times its book value
  • −Promoter holding has decreased over last quarter: -0.95%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Audio recording of Q2 and H1 FY27 earnings conference call released on 16 November 2026.

CARE report dated Nov. 13, 2026 flags 10-25% deviation in Rs 153.25 crore preferential issue proceeds.

Fredun Pharmaceuticals reports no deviation in use of ₹128.78 crore preferential issue proceeds for quarter ended 30 September 2026.

Intimation of Earnings Conference Call for the Quarter Q2 of FY27

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 82 87 118 79 0 167 120 145 161 213 228 268
Expenses + 72 76 107 68 0 150 103 123 135 184 196 225
Operating Profit 10 11 11 10 0 17 17 22 26 29 33 42
OPM % 12.0% 12.0% 9.0% 13.0% — 10.0% 14.0% 15.0% 16.0% 14.0% 14.0% 16.0%
Other Income + 0 0 0 0 0 0 0 0 0 0 0 0
Interest 3 4 4 4 0 8 7 8 11 14 9 9
Depreciation 1 1 1 1 0 2 1 2 2 3 4 4
Profit before tax 6 6 6 6 0 7 9 13 14 11 21 30
Tax % 32.0% 27.0% 13.0% 25.0% — 17.0% 25.0% 26.0% 25.0% 4.0% 36.0% 37.0%
Net Profit + 4 4 5 4 0 6 7 9 10 11 13 19
EPS in Rs 3 3 4 3 0 4 5 7 7 7 8 11
Raw PDF — — — — — — — — — — — —
YoY Sales growth 17 12 48 27 — — — — — 27 90 84

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026 TTM
Sales + 25 42 57 60 97 113 134 222 275 348 454 635 870
Expenses + 24 38 53 54 87 104 126 208 247 310 401 545 740
Operating Profit 2 4 3 6 10 8 8 14 28 38 52 91 130
OPM % 7.0% 9.0% 6.0% 10.0% 11.0% 7.0% 6.0% 6.0% 10.0% 11.0% 12.0% 14.0% 15.0%
Other Income + 0 1 2 0 0 1 1 2 2 1 2 4 0
Interest 1 2 2 2 3 4 4 5 9 14 22 39 42
Depreciation 1 1 1 1 1 2 2 2 3 4 5 8 12
Profit before tax 1 2 2 3 6 2 3 9 18 21 27 47 75
Tax % 52.0% 42.0% 36.0% 34.0% 28.0% 24.0% 37.0% 26.0% 38.0% 27.0% 28.0% 31.0% —
Net Profit + 0 1 1 2 4 2 2 6 11 16 20 33 53
EPS in Rs 0 2 2 2 4 2 2 5 8 11 14 20 32
Dividend Payout % 0.0% 13.0% 10.0% 12.0% 6.0% 14.0% 14.0% 5.0% 3.0% 2.0% 2.0% 1.0% —
Sales growth 19 67 34 5 63 16 19 66 24 27 — 40 —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026 Sep 2026
Reserves 0 1 2 19 35 37 39 64 92 117 137 273 314
Borrowings + 9 16 21 10 19 35 40 53 87 106 167 222 253
Other Liabilities + 11 24 30 47 47 65 79 66 74 81 179 142 190
Total Liabilities 23 43 56 79 105 141 162 187 257 308 487 642 774
Fixed Assets + 8 15 16 16 31 31 30 32 39 47 53 118 153
CWIP 1 0 4 11 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 0 1 2 2 3
Other Assets + 14 29 36 52 74 110 131 155 218 260 433 522 619
Total Assets 23 43 56 79 105 141 162 187 257 308 487 642 774
Equity Capital 2 2 2 3 4 4 4 4 5 5 5 5 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026
Cash from Operating Activity + 2 3 4 17 1 -11 0 -2 -14 0 -17 12
Cash from Investing Activity + -3 -6 -7 -8 -5 -1 -1 -4 -9 -8 -6 -74
Cash from Financing Activity + 1 3 3 -8 4 14 -1 7 25 6 27 121
Net Cash Flow 0 1 -1 1 0 2 -2 1 1 -2 4 60
Free Cash Flow -1 -3 -3 9 -4 -12 -1 -7 -24 -8 -23 -62
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 108 85 117 303 8 -128 2 -17 -52 -1 -32 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 49.16% → 43.62%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 49.24% 49.24% 49.23% 49.47% 49.47% 49.47% 49.49% 49.46% 53.0% 51.94% 51.45% 52.25%
Promoters 49.16% 49.17% 49.17% 48.93% 48.93% 48.93% 48.93% 48.93% 43.06% 44.17% 44.57% 43.62%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.01% 0.46% 1.06% 1.06% 0.69%
DII 1.6% 1.6% 1.6% 1.59% 1.59% 1.59% 1.59% 1.61% 3.48% 2.83% 2.94% 3.43%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Fredun Pharmaceuticals L (this stock) 2,548 48.1 7.59 15.6%
Hikal Limited 2,690 37.8 2.28 2.21%
Vimta Labs Limited 2,230 36.7 6.46 13.5%
Ind Swift Laboratories Lt 2,881 31.4 1.95 4.02%
Sai Parenterals Limited 2,189 87.8 4.42 4.88%
Dishman Carbo Amcis Ltd 2,183 151.0 0.33 1.58%
Sakar Healthcare Limited 2,172 50.7 6.26 9.99%

Which Mutual Funds Hold Fredun Pharmaceuticals L?

Frequently Asked Questions about Fredun Pharmaceuticals L

Community Sentiment

What are other investors saying about Fredun Pharmaceuticals L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.